Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Pearl

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Nature Biotechnology|March 8, 2016
Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous diseaseSuk See De Ravin, Andreas Reik, Pei-Qi Liu, et al.
Human Molecular Genetics|March 24, 2017
High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgroundsSeth A Ament, Jocelynn R Pearl, Andrea Grindeland, et al.
Nature Medicine|July 3, 2019
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's diseaseBryan Zeitler, Steven Froelich, Kimberly Marlen, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Nature Biotechnology|March 8, 2016
Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous diseaseSuk See De Ravin, Andreas Reik, Pei-Qi Liu, et al.
Human Molecular Genetics|March 24, 2017
High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgroundsSeth A Ament, Jocelynn R Pearl, Andrea Grindeland, et al.
Nature Medicine|July 3, 2019
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's diseaseBryan Zeitler, Steven Froelich, Kimberly Marlen, et al.
Pageof 9